Global Blood Therapeutics, INC.
A biopharmaceutical company with an FDA-approved medicine to treat sickle cell disease
Based in CA
AI Overview
With $0 in lobbying spend across 7 quarterly filings, Global Blood Therapeutics, INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2021 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Global Blood Therapeutics, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Advocating for U.S. government support for treatment of sickle cell disease in developing countries
Seeking support to help GBT develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.